Scott Hessen, MD
Clinical Cardiac Electrophysiology · Philadelphia, PANPI 1184697914
Payments from drug & device makers
Across 107 payments — averaging $225.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$12K
- Sanofi-aventis U.S. LLC$8K
- Johnson & Johnson$2K
- Pfizer$223
- Novartis$212
- Amgen$140
- plus $2K from 24 others
Across 2 payments — averaging $2739.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$5K
What the payments were for
- Consulting fees$8,14665%
- Food & beverage$4,35835%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 2 | $11,635 |
| Sanofi-aventis U.S. LLC | 7 | $8,336 |
| Johnson & Johnson | 22 | $1,824 |
| Pfizer | 11 | $223 |
| Novartis | 10 | $212 |
| Amgen | 8 | $140 |
| Impulse Dynamics (USA) Inc. | 1 | $135 |
| Edwards Lifesciences | 1 | $131 |
| Endotronix, Inc. | 1 | $127 |
| AstraZeneca | 5 | $119 |
| Kaneka Medical America LLC | 1 | $112 |
| Abbott | 1 | $111 |
| E.r. Squibb & Sons, L.L.C. | 6 | $108 |
| Infobionic, Inc | 1 | $106 |
| Kestra Medical Technology Services, Inc. | 3 | $98 |
| Medtronic | 4 | $91 |
| Bridgebio Pharma, Inc. | 4 | $90 |
| Boston Scientific | 2 | $78 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $72 |
| Alnylam Pharmaceuticals Inc. | 2 | $55 |
| Cardiva Medical, Inc. | 1 | $50 |
| Boehringer Ingelheim | 2 | $47 |
| Atricure, Inc. | 1 | $46 |
| Scpharmaceuticals Inc. | 1 | $45 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Novo Nordisk | 1 | $29 |
| GSK | 1 | $27 |
| Chiesi USA, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISEASE STATE$4,971
- MULTAQ$3,296
- XARELTO$935
- OPTIMIZER SMART SYSTEM$135
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$131
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$127
- ENSITE PRECISION$111
- MoMe Kardia$106
How this compares
$24,139 in reported general payments places this provider in the 45th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $224,563 |
| XareltoRivaroxaban | 113 | $143,291 |
| EntrestoSacubitril/Valsartan | 67 | $89,395 |
| JardianceEmpagliflozin | 23 | $20,429 |
| FarxigaDapagliflozin Propanediol | 14 | $12,025 |
| Dofetilide | 18 | $6,615 |
| Metoprolol Succinate | 261 | $3,734 |
| Atorvastatin Calcium | 251 | $3,323 |
| Ezetimibe | 76 | $2,900 |
| Rosuvastatin Calcium | 137 | $2,411 |
| Carvedilol | 121 | $1,848 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 32 | $1,640 |
| Flecainide Acetate | 22 | $1,467 |
| Propafenone Hcl | 30 | $1,426 |
| Amiodarone Hcl | 90 | $1,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $223 | $224,563202 claims |
| Johnson & JohnsonXarelto | $1,824 | $143,291113 claims |
| NovartisEntresto | $212 | $89,39567 claims |
| Boehringer IngelheimJardiance | $47 | $20,42923 claims |
| AstraZenecaFarxiga | $119 | $12,02514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Philadelphia
- Pasquale SantangeliPhiladelphia$1.3M
- Francis MarchlinskiPhiladelphia$1.2M
- David FrankelPhiladelphia$722K
- Fermin GarciaPhiladelphia$713K
- Timothy MarkmanPhiladelphia$693K
- Ralph VerdinoPhiladelphia$682K
- Robert SchallerPhiladelphia$579K
- Rajat DeoPhiladelphia$519K
- Matthew HymanPhiladelphia$474K
- Joshua CooperPhiladelphia$405K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.